This document is an excerpt from the EUR-Lex website
Document C:2007:039:FULL
Official Journal of the European Union, C 39, 23 February 2007
Official Journal of the European Union, C 39, 23 February 2007
Official Journal of the European Union, C 39, 23 February 2007
|
ISSN 1725-2423 |
||
|
Official Journal of the European Union |
C 39 |
|
|
||
|
English edition |
Information and Notices |
Volume 50 |
|
Notice No |
Contents |
page |
|
|
I Resolutions, recommendations, guidelines and opinions |
|
|
|
OPINIONS |
|
|
|
European Central Bank |
|
|
2007/C 039/01 |
||
|
|
II Information |
|
|
|
INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES |
|
|
|
Commission |
|
|
2007/C 039/02 |
Non-opposition to a notified concentration (Case COMP/M.4445 — voestalpine/Stamptec) ( 1 ) |
|
|
2007/C 039/03 |
Non-opposition to a notified concentration (Case COMP/M.4431 — BG Group/Serene) ( 1 ) |
|
|
2007/C 039/04 |
Non-opposition to a notified concentration (Case COMP/M.4510 — L Capital 2/Calligaris) ( 1 ) |
|
|
2007/C 039/05 |
Non-opposition to a notified concentration (Case COMP/M.4319 — Mondi/Schleipen & Erkens) ( 1 ) |
|
|
2007/C 039/06 |
Non-opposition to a notified concentration (Case COMP/M.4314 — Johnson & Johnson/Pfizer Consumer Healthcare) ( 1 ) |
|
|
2007/C 039/07 |
Non-opposition to a notified concentration (Case COMP/M.4526 — PAI/Lafarge) ( 1 ) |
|
|
|
IV Notices |
|
|
|
NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES |
|
|
|
Commission |
|
|
2007/C 039/08 |
||
|
2007/C 039/09 |
||
|
2007/C 039/10 |
||
|
|
NOTICES FROM MEMBER STATES |
|
|
2007/C 039/11 |
Publication of decisions by Member States to grant or revoke operating licenses pursuant to Article 13(4) of Council Regulation (EEC) No 2407/92 on licensing of air carriers ( 1 ) |
|
|
|
V Announcements |
|
|
|
PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMMON COMMERCIAL POLICY |
|
|
|
Commission |
|
|
2007/C 039/12 |
||
|
|
PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY |
|
|
|
Commission |
|
|
2007/C 039/13 |
Prior notification of a concentration (Case COMP/M.4469 — Scholz/voestalpine/Scholz Austria) ( 1 ) |
|
|
2007/C 039/14 |
Prior notification of a concentration (Case COMP/M.4522 — Carrefour/Ahold Polska) ( 1 ) |
|
|
|
||
|
2007/C 039/15 |
||
|
|
|
|
|
(1) Text with EEA relevance |
|
EN |
|
I Resolutions, recommendations, guidelines and opinions
OPINIONS
European Central Bank
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/1 |
OPINION OF THE EUROPEAN CENTRAL BANK
of 15 February 2007
at the request of the Council of the European Union on eight proposals amending Directives 2006/49/EC, 2006/48/EC, 2005/60/EC, 2004/109/EC, 2004/39/EC, 2003/71/EC, 2003/6/EC and 2002/87/EC, as regards the implementing powers conferred on the Commission
(CON/2007/4)
(2007/C 39/01)
Introduction and legal basis
On 29 and 31 January 2007 the European Central Bank (ECB) received requests from the Council of the European Union for an opinion on eight proposals for directives (1) in the financial field (hereinafter ‘the proposals’) whose main objectives are to amend the comitology provisions of eight existing directives to incorporate provisions on a new comitology procedure (the ‘regulatory procedure with scrutiny’), following the adoption of Council Decision 2006/512/EC of 17 July 2006 amending Decision 1999/468/EC laying down the procedures for the exercise of implementing powers conferred on the Commission (2), and to repeal the provisions of the eight existing directives that provide for a time limit for the delegation of implementing powers to the Commission (the so-called ‘sunset clauses’). The ECB's competence to deliver an opinion is based on Article 105(4) of the Treaty establishing the European Community. In accordance with the first sentence of Article 17(5) of the Rules of Procedure of the European Central Bank, the Governing Council has adopted this opinion.
1. Observations
|
1.1 |
The ECB welcomes the new agreement on comitology reached between the European Parliament, the Council and the Commission, which is of great importance for the continued functioning of the Lamfalussy process. |
|
1.2 |
The ECB has no specific comments on the proposals which are in line with the joint statement of the European Parliament, the Council and the Commission on the introduction of the new ‘regulatory procedure with scrutiny’ into the comitology framework (3). |
|
1.3 |
Having regard to the importance of the role played by implementing measures in EU legislation in the financial services field, the ECB takes this opportunity to underline the importance of its advisory role under Article 105(4) of the Treaty, which requires the ECB to be consulted ‘on any proposed Community act in its fields of competence’. As recently noted (4), ‘the ECB considers that proposed Level 2 acts constitute “proposed Community acts” within the meaning of Article 105(4) of the Treaty’ (5). Therefore the Treaty provision which requires the ECB to be consulted on any proposed Community act in its field of competence includes an obligation for it to be consulted on these implementing acts (6). |
Done at Frankfurt am Main, 15 February 2007.
The President of the ECB
Jean-Claude TRICHET
(1) (1) Proposal for a Directive of the European Parliament and of the Council amending Directive 2006/49/EC on the capital adequacy of investment firms and credit institutions, as regards the implementing powers conferred on the Commission (COM(2006) 90l final); (2) Proposal for a Directive of the European Parliament and of the Council amending Directive 2006/48/EC relating to the taking up and pursuit of the business of credit institutions, as regards the implementing powers conferred to the Commission (COM(2006) 902 final); (3) Proposal for a Directive of the European Parliament and of the Council amending Directive 2005/60/EC on the prevention of the use of the financial system for the purpose of money laundering and terrorist financing, as regards the implementing powers conferred on the Commission (COM(2006) 906 final); (4) Proposal for a Directive of the European Parliament and of the Council amending Directive 2004/109/EC relating to the harmonisation of transparency requirements in relation to information about issuers whose securities are admitted to trading on a regulated market as regards the implementing powers conferred on the Commission (COM(2006) 909 final); (5) Proposal for a Directive of the European Parliament and of the Council amending Directive 2004/39/EC relating to markets in financial instruments as regards the implementing powers conferred on the Commission (COM(2006) 910 final); (6) Proposal for a Directive of the European Parliament and of the Council amending Directive 2003/71/EC relating to the prospectus to be published when securities are offered to the public or admitted to trading, as regards the implementing powers conferred on the Commission (COM(2006) 911 final); (7) Proposal for a Directive of the European Parliament and of the Council amending Directive 2003/6/EC on insider dealing and market manipulation (market abuse), as regards the implementing powers conferred on the Commission (COM(2006) 913 final); (8) Proposal for a Directive of the European Parliament and of the Council amending Directive 2002/87/EC relating to the supplementary supervision of credit institutions, insurance undertakings and investment firms in a financial conglomerate as regards the implementing powers conferred on the Commission (COM(2006) 916 final).
(2) OJ L 200, 22.7.2006, p. 11.
(3) Statement by the European Parliament, the Council and the Commission concerning the Council Decision of 17 July 2006 amending Decision 1999/468/EC laying down the procedures for the exercise of implementing powers conferred on the Commission (2006/512/EC), (OJ C 255, 21.10.2006, p. 1).
(4) ECB Opinion CON/2006/57 of 12 December 2006 on a draft Commission Directive implementing Council Directive 85/611/EEC on the coordination of laws, regulations and administrative provisions relating to undertakings for collective investment in transferable securities (UCITS) as regards the clarification of certain definitions.
(5) Under the Lamfalussy framework the implementing acts are referred as ‘Level 2 acts’.
(6) The lack of consultation between Community institutions has been the subject of several judgments by the Court of Justice. On the obligation to consult the European Parliament, see Case 138/79 Roquette Frères [1980] ECR 3333 and Case C-21/94 Parliament v Council [1995] ECR I-1827, paragraph 17. On the obligation of the High Authority to consult the Council and the Consultative Committee under the ECSC Treaty, see Case 1/54 France v High Authority [1954-56] ECR 1, at p 15 and Case 2/54 Italy v High Authority [1954-56] ECR 37, at p 52, which was confirmed by Case 6/54 Netherlands v High Authority [1954-56] ECR 103, at p 112. As far as Article 105(4) of the Treaty is concerned, in Case C-11/00 Commission v European Central Bank [2003] ECR I-7147, Advocate General Jacobs emphasised that: ‘Consultation of the ECB on proposed measures in its field of competence is a procedural step, required by a provision of the Treaty, which is clearly capable of affecting the content of the measures adopted. Failure to comply with such requirement must, in my view, be capable of leading to the annulment of the measures adopted’, Opinion of Advocate General Jacobs given on 3 October 2002, paragraph 131.
II Information
INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES
Commission
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/3 |
Non-opposition to a notified concentration
(Case COMP/M.4445 — voestalpine/Stamptec)
(Text with EEA relevance)
(2007/C 39/02)
On 6 February 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:
|
— |
from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
|
— |
in electronic form on the EUR-Lex website under document number 32007M4445. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu) |
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/3 |
Non-opposition to a notified concentration
(Case COMP/M.4431 — BG Group/Serene)
(Text with EEA relevance)
(2007/C 39/03)
On 1 February 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:
|
— |
from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
|
— |
in electronic form on the EUR-Lex website under document number 32007M4431. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu) |
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/4 |
Non-opposition to a notified concentration
(Case COMP/M.4510 — L Capital 2/Calligaris)
(Text with EEA relevance)
(2007/C 39/04)
On 12 February 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:
|
— |
from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
|
— |
in electronic form on the EUR-Lex website under document number 32007M4510. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu) |
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/4 |
Non-opposition to a notified concentration
(Case COMP/M.4319 — Mondi/Schleipen & Erkens)
(Text with EEA relevance)
(2007/C 39/05)
On 24 October 2006, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:
|
— |
from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
|
— |
in electronic form on the EUR-Lex website under document number 32006M4319. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu) |
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/5 |
Non-opposition to a notified concentration
(Case COMP/M.4314 — Johnson & Johnson/Pfizer Consumer Healthcare)
(Text with EEA relevance)
(2007/C 39/06)
On 11 December 2006, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(2) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:
|
— |
from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
|
— |
in electronic form on the EUR-Lex website under document number 32006M4314. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu) |
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/5 |
Non-opposition to a notified concentration
(Case COMP/M.4526 — PAI/Lafarge)
(Text with EEA relevance)
(2007/C 39/07)
On 15 February 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:
|
— |
from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
|
— |
in electronic form on the EUR-Lex website under document number 32007M4526. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu) |
IV Notices
NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES
Commission
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/6 |
Euro exchange rates (1)
22 February 2007
(2007/C 39/08)
1 euro=
|
|
Currency |
Exchange rate |
|
USD |
US dollar |
1,3106 |
|
JPY |
Japanese yen |
159,00 |
|
DKK |
Danish krone |
7,4555 |
|
GBP |
Pound sterling |
0,67190 |
|
SEK |
Swedish krona |
9,3155 |
|
CHF |
Swiss franc |
1,6281 |
|
ISK |
Iceland króna |
87,15 |
|
NOK |
Norwegian krone |
8,0635 |
|
BGN |
Bulgarian lev |
1,9558 |
|
CYP |
Cyprus pound |
0,5792 |
|
CZK |
Czech koruna |
28,237 |
|
EEK |
Estonian kroon |
15,6466 |
|
HUF |
Hungarian forint |
251,67 |
|
LTL |
Lithuanian litas |
3,4528 |
|
LVL |
Latvian lats |
0,7057 |
|
MTL |
Maltese lira |
0,4293 |
|
PLN |
Polish zloty |
3,8762 |
|
RON |
Romanian leu |
3,3815 |
|
SKK |
Slovak koruna |
34,286 |
|
TRY |
Turkish lira |
1,8110 |
|
AUD |
Australian dollar |
1,6610 |
|
CAD |
Canadian dollar |
1,5214 |
|
HKD |
Hong Kong dollar |
10,2376 |
|
NZD |
New Zealand dollar |
1,8560 |
|
SGD |
Singapore dollar |
2,0108 |
|
KRW |
South Korean won |
1 230,52 |
|
ZAR |
South African rand |
9,2551 |
|
CNY |
Chinese yuan renminbi |
10,1475 |
|
HRK |
Croatian kuna |
7,3433 |
|
IDR |
Indonesian rupiah |
11 900,90 |
|
MYR |
Malaysian ringgit |
4,5805 |
|
PHP |
Philippine peso |
63,302 |
|
RUB |
Russian rouble |
34,3900 |
|
THB |
Thai baht |
44,460 |
Source: reference exchange rate published by the ECB.
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/7 |
Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 January 2007 to 31 January 2007
(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1) )
(2007/C 39/09)
— Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
|||||
|
4.1.2007 |
ADROVANCE |
Alendronate sodium/Colecalciferol |
|
EU/1/06/364/001-005 |
Tablet |
(Non applicable) |
9.1.2007 |
|||||
|
4.1.2007 |
Diacomit |
Stiripentol |
|
EU/1/06/367/001-006 |
Capsule |
N03AX17 |
9.1.2007 |
|||||
|
EU/1/06/367/007-012 |
Powder for oral suspension |
|||||||||||
|
8.1.2007 |
Elaprase |
Idursulfase |
|
EU/1/06/365/001-003 |
Concentrate for solution for infusion |
A16AB09 |
10.1.2007 |
|||||
|
8.1.2007 |
Tandemact |
Pioglitazone/Glimepiride |
|
EU/1/06/366/001-004 |
Tablet |
(Non applicable) |
10.1.2007 |
|||||
|
16.1.2007 |
Inovelon |
rufinamide |
|
EU/1/06/378/001-016 |
Film-coated tablet |
N03AF03 |
18.1.2007 |
|||||
|
16.1.2007 |
Dafiro |
amlodipine/valsartan |
|
EU/1/06/371/001-024 |
Film-coated tablet |
C09DB01 |
18.1.2007 |
|||||
|
16.1.2007 |
Copalia |
amlodipine/valsartan |
|
EU/1/06/372/001-024 |
Film-coated tablet |
C09DB01 |
18.1.2007 |
|||||
|
17.1.2007 |
Exforge |
amlodipine/valsartan |
|
EU/1/06/370/001-024 |
Film-coated tablet |
C09DB01 |
19.1.2007 |
|||||
|
17.1.2007 |
Imprida |
amlodipine/valsartan |
|
EU/1/06/373/001-024 |
Film-coated tablet |
C09DB01 |
19.1.2007 |
|||||
|
17.1.2007 |
Insulin Human Winthrop |
insulin human |
|
EU/1/06/368/001-002 EU/1/06/368/011-015 EU/1/06/368/056-057 |
Solution for injection |
A10AB01 |
2.2.2007 |
|||||
|
EU/1/06/368/003-010 EU/1/06/368/020-024 EU/1/06/368/029-033 EU/1/06/368/038-042 EU/1/06/368/047-051 |
Suspension for injection |
|||||||||||
|
EU/1/06/368/016-019 EU/1/06/368/025-028 EU/1/06/368/034-037 EU/1/06/368/043-046 EU/1/06/368/052-055 |
OptiSet, solution for injection |
|||||||||||
|
19.1.2007 |
Irbesartan BMS |
irbesartan |
|
EU/1/06/375/001-015 |
Tablet |
C09CA04 |
23.1.2007 |
|||||
|
EU/1/06/375/016-033 |
Film-coated tablets |
|||||||||||
|
19.1.2007 |
Irbesartan Hydrochlorothiazide BMS |
irbesartan/hydrochlorothiazide |
|
EU/1/06/369/001-010 |
Tablet |
C09DA04 |
23.1.2007 |
|||||
|
EU/1/06/369/011-028 |
Film-coated tablets |
|||||||||||
|
19.1.2007 |
Irbesartan Winthrop |
Irbesartan |
|
EU/1/06/376/001-015 |
Tablet |
C09CA04 |
23.1.2007 |
|||||
|
EU/1/06/376/016-033 |
Film-coated tablets |
|||||||||||
|
19.1.2007 |
Irbesartan Hydrochlorothiazide Winthrop |
irbesartan/hydrochlorothiazide |
|
EU/1/06/377/001-010 |
Tablet |
C09DA04 |
23.1.2007 |
|||||
|
EU/1/06/377/011-028 |
Film-coated tablets |
|||||||||||
|
22.1.2007 |
Lucentis |
ranibizumab |
|
EU/1/06/374/001 |
Solution for injection |
S01LA04 |
24.1.2007 |
— Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Rejected
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
|||
|
16.1.2007 |
Thymanax |
|
— |
18.1.2007 |
|||
|
16.1.2007 |
Valdoxan |
|
— |
18.1.2007 |
— Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
||||||
|
3.1.2007 |
MicardisPlus |
|
EU/1/02/213/001-016 |
9.1.2007 |
||||||
|
3.1.2007 |
Neulasta |
|
EU/1/02/227/001-003 |
9.1.2007 |
||||||
|
3.1.2007 |
Neupopeg |
|
EU/1/02/228/001-003 |
9.1.2007 |
||||||
|
3.1.2007 |
Invirase |
|
EU/1/96/026/001-002 |
9.1.2007 |
||||||
|
3.1.2007 |
Ceprotin |
|
EU/1/01/190/001-002 |
9.1.2007 |
||||||
|
3.1.2007 |
Ambirix |
|
EU/1/02/224/ 001-005 |
9.1.2007 |
||||||
|
3.1.2007 |
Velcade |
|
EU/1/04/274/001 |
9.1.2007 |
||||||
|
3.1.2007 |
Zostavax |
|
EU/1/06/341/001-013 |
9.1.2007 |
||||||
|
3.1.2007 |
Nexavar |
|
EU/1/06/342/001 |
9.1.2007 |
||||||
|
3.1.2007 |
Telzir |
|
EU/1/04/282/001-002 |
9.1.2007 |
||||||
|
4.1.2007 |
Twinrix Paediatric |
|
EU/1/97/029/001-010 |
9.1.2007 |
||||||
|
4.1.2007 |
NovoSeven |
|
EU/1/96/006/001-003 |
9.1.2007 |
||||||
|
4.1.2007 |
PEGASYS |
|
EU/1/02/221/001-010 |
9.1.2007 |
||||||
|
4.1.2007 |
Kinzalmono |
|
EU/1/98/091/001-014 |
9.1.2007 |
||||||
|
4.1.2007 |
Twinrix Adult |
|
EU/1/96/020/001-009 |
9.1.2007 |
||||||
|
4.1.2007 |
NeoRecormon |
|
EU/1/97/031/001-003 EU/1/97/031/019-046 |
9.1.2007 |
||||||
|
4.1.2007 |
Micardis |
|
EU/1/98/090/001-020 |
9.1.2007 |
||||||
|
4.1.2007 |
Rebetol |
|
EU/1/99/107/001-005 |
9.1.2007 |
||||||
|
4.1.2007 |
Competact |
|
EU/1/06/354/001-009 |
9.1.2007 |
||||||
|
4.1.2007 |
Remicade |
|
EU/1/99/116/001-003 |
9.1.2007 |
||||||
|
4.1.2007 |
Ketek |
|
EU/1/01/191/001-005 |
9.1.2007 |
||||||
|
4.1.2007 |
Levviax |
|
EU/1/01/192/001-005 |
9.1.2007 |
||||||
|
4.1.2007 |
Temodal |
|
EU/1/98/096/001-008 |
9.1.2007 |
||||||
|
4.1.2007 |
Keppra |
|
EU/1/00/146/001-030 |
10.1.2007 |
||||||
|
4.1.2007 |
Kinzalkomb |
|
EU/1/02/214/001-010 |
9.1.2007 |
||||||
|
8.1.2007 |
PritorPlus |
|
EU/1/02/215/001-014 |
10.1.2007 |
||||||
|
8.1.2007 |
Pritor |
|
EU/1/98/089/001-022 |
10.1.2007 |
||||||
|
8.1.2007 |
DepoCyte |
|
EU/1/01/187/001 |
10.1.2007 |
||||||
|
8.1.2007 |
Agenerase |
|
EU/1/00/148/001-004 |
10.1.2007 |
||||||
|
8.1.2007 |
IntronA |
|
EU/1/99/127/001-044 |
10.1.2007 |
||||||
|
8.1.2007 |
Viread |
|
EU/1/01/200/001 |
10.1.2007 |
||||||
|
9.1.2007 |
Puregon |
|
EU/1/96/008/001-041 |
11.1.2007 |
||||||
|
9.1.2007 |
Neupro |
|
EU/1/05/331/001-037 |
11.1.2007 |
||||||
|
9.1.2007 |
Viraferon |
|
EU/1/99/128/001-037 |
11.1.2007 |
||||||
|
9.1.2007 |
Thyrogen |
|
EU/1/99/122/001-002 |
11.1.2007 |
||||||
|
11.1.2007 |
Karvezide |
|
EU/1/98/085/001-028 |
15.1.2007 |
||||||
|
11.1.2007 |
CoAprovel |
|
EU/1/98/086/001-028 |
15.1.2007 |
||||||
|
11.1.2007 |
Sutent |
|
EU/1/06/347/001-003 |
15.1.2007 |
||||||
|
11.1.2007 |
Viracept |
|
EU/1/97/054/001 EU/1/97/054/003-005 |
15.1.2007 |
||||||
|
11.1.2007 |
Invirase |
|
EU/1/96/026/001-002 |
15.1.2007 |
||||||
|
11.1.2007 |
Karvezide |
|
EU/1/98/085/001-028 |
15.1.2007 |
||||||
|
12.1.2007 |
MabThera |
|
EU/1/98/067/001-002 |
16.1.2007 |
||||||
|
12.1.2007 |
Truvada |
|
EU/1/04/305/001 |
16.1.2007 |
||||||
|
12.1.2007 |
Emtriva |
|
EU/1/03/261/001-003 |
16.1.2007 |
||||||
|
12.1.2007 |
Norvir |
|
EU/1/96/016/001 EU/1/96/016/003-004 |
16.1.2007 |
||||||
|
15.1.2007 |
Stocrin |
|
EU/1/99/111/001-011 |
18.1.2007 |
||||||
|
15.1.2007 |
Viramune |
|
EU/1/97/055/001-003 |
18.1.2007 |
||||||
|
15.1.2007 |
Sustiva |
|
EU/1/99/110/001-009 |
18.1.2007 |
||||||
|
15.1.2007 |
Viread |
|
EU/1/01/200/001 |
18.1.2007 |
||||||
|
16.1.2007 |
Insuman |
|
EU/1/97/030/028-084 |
2.2.2007 |
||||||
|
16.1.2007 |
Kaletra |
|
EU/1/01/172/001-005 |
18.1.2007 |
||||||
|
17.1.2007 |
REYATAZ |
|
EU/1/03/267/001-007 |
19.1.2007 |
||||||
|
17.1.2007 |
Revatio |
|
EU/1/05/318/001 |
19.1.2007 |
||||||
|
17.1.2007 |
SUTENT |
|
EU/1/06/347/001-003 |
19.1.2007 |
||||||
|
17.1.2007 |
Kivexa |
|
EU/1/04/298/001-002 |
19.1.2007 |
||||||
|
17.1.2007 |
Lyrica |
|
EU/1/04/279/001-035 |
19.1.2007 |
||||||
|
17.1.2007 |
Advate |
|
EU/1/03/271/001-004 |
19.1.2007 |
||||||
|
17.1.2007 |
Ziagen |
|
EU/1/99/112/001-002 |
19.1.2007 |
||||||
|
18.1.2007 |
Telzir |
|
EU/1/04/282/001-002 |
22.1.2007 |
||||||
|
18.1.2007 |
Avaglim |
|
EU/1/06/349/001-008 |
22.1.2007 |
||||||
|
18.1.2007 |
Enbrel |
|
EU/1/99/126/001-018 |
22.1.2007 |
||||||
|
19.1.2007 |
Zerit |
|
EU/1/96/009/001-009 |
23.1.2007 |
||||||
|
24.1.2007 |
Stalevo |
|
EU/1/03/260/001-015 |
26.1.2007 |
||||||
|
24.1.2007 |
Paxene |
|
EU/1/99/113/001-004 |
26.1.2007 |
||||||
|
24.1.2007 |
Comtess |
|
EU/1/98/082/001-003 EU/1/98/082/005 |
26.1.2007 |
||||||
|
24.1.2007 |
Fuzeon |
|
EU/1/03/252/001-003 |
26.1.2007 |
||||||
|
24.1.2007 |
TRIZIVIR |
|
EU/1/00/156/002-003 |
26.1.2007 |
||||||
|
24.1.2007 |
Agenerase |
|
EU/1/00/148/001-004 |
26.1.2007 |
||||||
|
24.1.2007 |
Fabrazyme |
|
EU/1/01/188/001-006 |
26.1.2007 |
||||||
|
24.1.2007 |
Tarceva |
|
EU/1/05/311/001-003 |
26.1.2007 |
||||||
|
24.1.2007 |
Avandamet |
|
EU/1/03/258/001-022 |
26.1.2007 |
||||||
|
24.1.2007 |
Aptivus |
|
EU/1/05/315/001 |
26.1.2007 |
||||||
|
24.1.2007 |
Nexavar |
|
EU/1/06/342/001 |
26.1.2007 |
||||||
|
24.1.2007 |
Crixivan |
|
EU/1/96/024/001-005 EU/1/96/024/007-008 EU/1/96/024/010 |
26.1.2007 |
||||||
|
25.1.2007 |
Evra |
|
EU/1/02/223/001-003 |
29.1.2007 |
||||||
|
25.1.2007 |
Epivir |
|
EU/1/96/015/001-005 |
29.1.2007 |
||||||
|
26.1.2007 |
Alimta |
|
EU/1/04/290/001 |
30.1.2007 |
||||||
|
26.1.2007 |
Actos |
|
EU/1/00/150/001-024 |
30.1.2007 |
||||||
|
26.1.2007 |
Combivir |
|
EU/1/98/058/001-002 |
30.1.2007 |
||||||
|
26.1.2007 |
Helixate NexGen |
|
EU/1/00/144/001-003 |
30.1.2007 |
||||||
|
26.1.2007 |
TARGRETIN |
|
EU/1/01/178/001 |
30.1.2007 |
||||||
|
29.1.2007 |
KOGENATE Bayer |
|
EU/1/00/143/001-009 |
31.1.2007 |
||||||
|
31.1.2007 |
Avonex |
|
EU/1/97/033/001-003 |
2.2.2007 |
— Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
|||
|
9.1.2007 |
Cortavance |
Hydrocortisone aceponate |
|
EU/2/06/069/001 |
Cutaneous spray, solution |
QD07AC |
11.1.2007 |
|||
|
11.1.2007 |
Yposane |
Osaterone acetate |
|
EU/2/06/068/001-004 |
Tablets |
QG04CX |
15.1.2007 |
|||
|
15.1.2007 |
Meloxicam CEVA |
Meloxicam |
|
EU/2/06/070/001-003 |
oral suspension |
QM01AC06 |
18.1.2007 |
— Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
||||
|
4.1.2007 |
Previcox |
|
EU/2/04/045/001-006 |
9.1.2007 |
||||
|
16.1.2007 |
Equilis StrepE |
|
EU/2/04/043/001 |
18.1.2007 |
||||
|
11.1.2007 |
Gonazon |
|
EU/2/03/040/002 |
15.1.2007 |
||||
|
16.1.2007 |
Profender |
|
EU/2/05/054/001-017 |
18.1.2007 |
Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:
|
The European Medicines Agency |
|
7, Westferry Circus, Canary Wharf |
|
London E14 4HB |
|
United Kingdom |
(1) OJ L 136, 30.4.2004, p. 1.
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/18 |
Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 January 2007 to 31 January 2007
(Decisions taken pursuant to Article 34 of Directive 2001/83/EC (1) or Article 38 of Directive 2001/82/EC (2))
(2007/C 39/10)
— Issuing, maintenance or modification of a national marketing authorisation
|
Date of the decision |
Name(s) of the medicinal product |
Holder(s) of the marketing authorization |
Member State concerned |
Date of notification |
|||||
|
22.1.2007 |
Lucentis |
|
This Decision is addressed to the Member States |
24.1.2007 |
|||||
|
24.1.2007 |
Ciprofloxacin Kabi |
See Annex I |
See Annex I |
25.1.2007 |
(1) OJ L 311, 28.11.2001, p. 67.
(2) OJ L 311, 28.11.2001, p. 1.
ANNEX I
LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
|
Member State |
Marketing Authorisation Holder |
Applicant |
Name |
Strength |
Pharmaceutical Form |
Route of administration |
Content (concentration) |
|||||||
|
Netherlands |
|
|
Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
100 mg/50 ml |
|||||||
|
Netherlands |
|
|
Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Netherlands |
|
|
Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
Austria |
|
|
Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
100 mg/50 ml |
|||||||
|
Austria |
|
|
Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Austria |
|
|
Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
Belgium |
|
|
Ciprofloxacin Fresenius Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Belgium |
|
|
Ciprofloxacin Fresenius Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
Cyprus |
|
|
Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
100 mg/50 ml |
|||||||
|
Cyprus |
|
|
Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Cyprus |
|
|
Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
Czech Republic |
|
|
Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
100 mg/50 ml |
|||||||
|
Czech Republic |
|
|
Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Czech Republic |
|
|
Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
Germany |
|
|
Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
100 mg/50 ml |
|||||||
|
Germany |
|
|
Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Germany |
|
|
Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
Denmark |
|
|
Ciprofloxacin Fresenius Kabi 2 mg/ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml, 400 mg/200 ml |
|||||||
|
Greece |
|
|
Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
100 mg/50 ml |
|||||||
|
Greece |
|
|
Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Greece |
|
|
Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
Spain |
|
|
Ciprofloxacin Kabi 2 mg/ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml, 400 mg/200 ml |
|||||||
|
Finland |
|
|
Ciprofloxacin Fresenius Kabi 2 mg/ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml, 400 mg/200 ml |
|||||||
|
Hungary |
|
|
Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Hungary |
|
|
Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
Italy |
|
|
Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
100 mg/50 ml |
|||||||
|
Italy |
|
|
Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Italy |
|
|
Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
Poland |
|
|
Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
100 mg/50 ml |
|||||||
|
Poland |
|
|
Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Poland |
|
|
Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
Portugal |
|
|
Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
100 mg/50 ml |
|||||||
|
Portugal |
|
|
Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Portugal |
|
|
Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
Sweden |
|
|
Ciprofloxacin Fresenius Kabi 2 mg/ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml, 400 mg/200 ml |
|||||||
|
Slovak Republic |
|
|
Ciprofloxacin Kabi 100 mg/50 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
100 mg/50 ml |
|||||||
|
Slovak Republic |
|
|
Ciprofloxacin Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
Slovak Republic |
|
|
Ciprofloxacin Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
|||||||
|
United Kingdom |
|
|
Ciprofloxacine Kabi 100 mg/50 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
100 mg/50 ml |
|||||||
|
United Kingdom |
|
|
Ciprofloxacine Kabi 200 mg/100 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
200 mg/100 ml |
|||||||
|
United Kingdom |
|
|
Ciprofloxacine Kabi 400 mg/200 ml, solution for infusion |
2 mg/ml |
Solution for infusion |
Intravenous use |
400 mg/200 ml |
NOTICES FROM MEMBER STATES
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/25 |
Publication of decisions by Member States to grant or revoke operating licenses pursuant to Article 13(4) of Council Regulation (EEC) No 2407/92 on licensing of air carriers (1) (2)
(Text with EEA relevance)
(2007/C 39/11)
GERMANY
Operating licences granted
Category B: Operating licences including the restriction of Article 5(7)(a) of Regulation (EEC) No 2407/92
|
Name of air carrier |
Address of air carrier |
Permitted to carry |
Decision effective since |
||
|
Air Hamburg Luftverkehrsgesellschaft mbH |
|
passengers, mail, cargo |
13.12.2006 |
||
|
DVS Deutsche Verkehrsfliegerschule GmbH |
|
passengers, mail, cargo |
31.1.2007 |
Operating licences revoked
Category A: Operating licences without the restriction of Article 5(7)(a) of Regulation (EEC) No 2407/92
|
Name of air carrier |
Address of air carrier |
Permitted to carry |
Decision effective since |
||
|
Lufthansa Flight Training GmbH |
|
passengers, mail, cargo |
22.12.2006 |
||
|
Antares Airtransport Maintenance und Service AG |
|
passengers, mail, cargo |
31.1.2007 |
Category B: Operating licences including the restriction of Article 5(7)(a) of Regulation (EEC) No 2407/92
|
Name of air carrier |
Address of air carrier |
Permitted to carry |
Decision effective since |
||
|
Helicopter Medical Services |
|
passengers, mail, cargo |
21.12.2006 |
(2) Communicated to the European Commission before 31.8.2005.
V Announcements
PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMMON COMMERCIAL POLICY
Commission
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/26 |
Notice of initiation of a partial interim review of the antidumping measures applicable to imports of grain oriented flat-rolled products of silicon-electrical steel (GOES) originating in Russia
(2007/C 39/12)
The Commission has decided on its own initiative to initiate a partial interim review pursuant to Article 11(3) of Council Regulation (EC) No 384/96 on protection against dumped imports from countries not members of the European Community (‘the basic Regulation’) (1). The review is limited to the examination of the level of dumping for two Russian exporting producers, Novolipetsk Iron & Steel Corporation (NLMK) and Viz Stal.
1. Product
The product under review is grain oriented flat-rolled products of silicon-electrical steel originating in Russia (‘the product concerned’), currently classifiable within CN codes 7225 11 00 and 7226 11 00. These CN codes are given only for information.
2. Existing measures
The measures currently in force are a definitive anti-dumping duty imposed by Council Regulation (EC) No 1371/2005 (2) on imports of grain oriented flat-rolled products of silicon-electrical steel originating in Russia. By Decision No 2005/622/EC of 5 August 2005 (3), the Commission accepted an undertaking offered by Novolipetsk Iron & Steel Corporation. As a result, imports of the product concerned from this company are not subject to the definitive anti-dumping duty in accordance with Article 2 of Regulation (EC) No 1371/2005.
3. Grounds for the review
The Commission has been notified that NLMK has acquired 100 % of Viz Stal. In addition, evidence has been provided regarding production, sales and distribution of the product concerned under the new corporate structure. In view of this evidence, the circumstances on the basis of which measures were established appear to have changed in a lasting way.
The evidence at hand also shows that the dumping margin under the new corporate structure would change significantly as compared to the level of the current measures.
On the basis of the foregoing, it appears that the individual duties in force for NLMK (although duties are currently not collected for imports from this company for the reason set out in point 2 above) and Viz Stal are no longer appropriate, and that a review should be initiated ex officio in order to calculate one single measure for the new joint company.
4. Procedure for the determination of dumping
(a) General
Having determined, after consulting the Advisory Committee, that sufficient evidence exists to justify the initiation of a partial interim review, the Commission hereby initiates a review in accordance with Article 11 (3) of the basic Regulation.
The investigation will assess the need for the continuation, removal or amendment of the existing measures in respect of NLMK and Viz Stal under the new corporate structure. This assessment will be made on the basis of data collected during the investigation that lead to the imposition of the existing measures.
If it is determined that measures should be removed or amended for the companies concerned by this review under the new corporate structure, it may be necessary to amend the rate of duty currently applicable to imports from other exporting producers of the product concerned as set out in Article 1(2) of Council Regulation (EC) No 1371/2005.
(b) Collection of information and holding of hearings
All interested parties are hereby invited to make their views known, submit information and to provide supporting evidence. This information and supporting evidence must reach the Commission within the time limit set in point 6(a).
Furthermore, the Commission may hear interested parties, provided that they make a request showing that there are particular reasons why they should be heard. This request must be made within the time limit set in point 6(b).
5. Time limits
(a) For parties to make themselves known and to submit any other information
All interested parties, if their representations are to be taken into account during the investigation, must make themselves known by contacting the Commission, present their views and submit any other information within 40 days of the date of publication of this notice in the Official Journal of the European Union, unless otherwise specified. Attention is drawn to the fact that the exercise of most procedural rights set out in the basic Regulation depends on the party's making itself known within the aforementioned period.
(b) Hearings
All interested parties may also apply to be heard by the Commission within the same 40-day time limit.
6. Written submissions and correspondence
All submissions and requests made by interested parties must be made in writing (not in electronic format, unless otherwise specified) and must indicate the name, address, e-mail address, telephone and fax numbers of the interested party. All written submissions, including the information requested in this notice and correspondence provided by interested parties on a confidential basis shall be labelled as ‘Limited (4)’ and, in accordance with Article 19(2) of the basic Regulation, shall be accompanied by a non-confidential version, which will be labelled ‘FOR INSPECTION BY INTERESTED PARTIES’.
Commission address for correspondence:
|
European Commission |
|
Directorate General for Trade |
|
Directorate B |
|
Office: J-79 5/16 |
|
B-1049 Brussels |
|
Fax: (32-2) 295 65 05 |
7. Non-co-operation
In cases in which any interested party refuses access to or does not provide the necessary information within the time limits, or significantly impedes the investigation, findings, affirmative or negative, may be made in accordance with Article 18 of the basic Regulation, on the basis of the facts available.
Where it is found that any interested party has supplied false or misleading information, the information shall be disregarded and use may be made, in accordance with Article 18 of the basic Regulation, of the facts available. If an interested party does not cooperate or cooperates only partially, and use of facts available is made, the result may be less favourable to that party than if it had cooperated.
8. Schedule of the investigation
The investigation will be concluded, according to Article 6(9) of the basic Regulation within 15 months of the date of the publication of this notice in the Official Journal of the European Union.
(1) OJ L 56, 6.3.1996, p. 1. Regulation as last amended by Regulation (EC) No 2117/2005 (OJ L 340, 23.12.2005, p. 17.).
(2) OJ L 223, 27.8.2005, p. 1.
(3) OJ L 223, 27.8.2005, p. 42.
(4) This means that the document is for internal use only. It is protected pursuant to Article 4 of Regulation (EC) No 1049/2001 of the European Parliament and of the Council regarding public access to European Parliament, Council and Commission documents (OJ L 145, 31.5.2001, p. 43). It is a confidential document pursuant to Article 19 of the basic Regulation and Article 6 of the WTO Agreement on Implementation of Article VI of the GATT 1994 (Anti-dumping Agreement).
PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY
Commission
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/28 |
Prior notification of a concentration
(Case COMP/M.4469 — Scholz/voestalpine/Scholz Austria)
(Text with EEA relevance)
(2007/C 39/13)
|
1. |
On 15 February 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Scholz AG (‘Scholz’, Germany) and voestalpine AG (‘voestalpine’, Austria) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of Scholz Austria GmbH (‘Scholz Austria’, Austria) by means of purchase of shares in a newly created company constituting a joint venture. |
|
2. |
The business activities of the undertakings concerned are:
|
|
3. |
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
|
4. |
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No (32-2) 296 43 01 or 296 72 44) or by post, under reference number Case COMP/M.4469 — Scholz/voestalpine/Scholz Austria, to the following address: |
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
J-70 |
|
B-1049 Bruxelles/Brussel |
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/29 |
Prior notification of a concentration
(Case COMP/M.4522 — Carrefour/Ahold Polska)
(Text with EEA relevance)
(2007/C 39/14)
|
1. |
On 16 February 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Carrefour Nederland BV (‘Carrefour Nederland’, Netherlands), belonging to the group Carrefour (‘Carrefour’, France), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Ahold Polska Sp. z o.o (‘Ahold Polska’, Poland) by way of purchase of shares. |
|
2. |
The business activities of the undertakings concerned are:
|
|
3. |
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
|
4. |
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4522 — Carrefour/Ahold Polska, to the following address:
|
|
23.2.2007 |
EN |
Official Journal of the European Union |
C 39/s3 |
NOTICE
On 23 February 2007, in Official Journal of the European Union C 39 A, the ‘Common catalogue of agricultural plant species —25th complete edition’ will be published.
Subscribers to the Official Journal may obtain the same number of copies and language versions of this Official Journal as those to which they subscribe free of charge. They are requested to return the attached order form, duly completed and bearing their subscription registration number (code appearing on the left of each label and beginning with: O/…). This Official Journal will remain available free of charge for one year from the date of its publication.
Non-subscribers can order this Official Journal against payment from one of our sales offices (see http://publications.europa.eu/others/sales_agents_en.html).
This Official Journal — like all Official Journals (L,C,CA,CE) — can be consulted free of charge online at http://eur-lex.europa.eu.